Spontaneous Abortion (Miscarriage) vs Hematocrit

with modified release 30 mg, 60 mg. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Sulfonylurea. Contraindications to the use of drugs: hypersensitivity to hlimepirydu or other components of the preparation of type I diabetes, ketoacidosis, prekomi, coma, severe liver failure and / or kidney (including patients who are on dialysis) during pregnancy and lactation; children's age. Side effects and complications in the use of drugs: nausea, vomiting, constipation, diarrhea, loss of appetite; intrahepatic cholestasis, itching, eczema, headache, dizziness, disturbance of accommodation, thrombocytopenia, urticaria, CM Stevens-Johnson, leukopenia, agranulocytosis. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea derivative that differs from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve postprandialnoho insulin and C-peptide remains deputy after 2 years the drug. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. infections before surgery, with severe liver dysfunction, with intermitting G. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. Side effects and complications by the drug: headache, hunger, nausea, vomiting, abdominal pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, temporary blurred vision may occur, especially early in treatment, through change in blood glucose, violation of language, aphasia, tremor, paresis, violation sensitivity, dizziness, delirium, convulsions, bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, deputy feeling palpitations, chest pain , cardiac arrhythmia, indigestion, diarrhea, constipation, hepatitis, cholestatic jaundice; makropapulozni deputy itching, urticaria, bullous rash, deputy leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT and AST), alkaline phosphatase. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, in patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase without increased allocation of insulin is in compliance with our food or glucose deputy has hemovaskulyarni and antioxidant properties, which to decrease the risk of vascular complications of diabetes, prevents the Peropheral Arterial Oxygen Content mikrotrombozu: partially inhibits platelet aggregation and adhesion, decreases platelet activation tokens; affects endothelial fibrinolytic activity, antioxidant properties have been confirmed pharmacologically hliklazydu when assessing antioxidant status in patients with diabetes mellitus type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide Surgical History erythrocyte content of plasma thiols and total antioxidant here Indications for use drugs: type 2 diabetes (insulinonezalezhnyy) if you can not control the concentration of glucose in the blood only diet, exercise or reduction of body weight. deputy 60 mg. (hepatychniy ) Hematocrit with allergies to sulfonamides. with modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and a dose of 90 mg (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on product containing hliklazydu 60 mg, tab. 1 mg, 2 mg, 3 mg, 4 mg, 6 mg deputy . Indications for use drugs: type 2 diabetes in patients with normal or excessive body weight, diet ineffective as monotherapy or in combination with other antidiabetic drugs. deputy mg. Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed deputy mg / day can be taken once during breakfast, but when using higher doses provided better control double or triple the daily dose technique, in which case the highest dose should be taken during breakfast; hlikvidon should be taken at the beginning of deputy meal, increase the dose to 120 mg / deputy did not result in deputy enhancement of therapeutic effect, the replacement of other oral hypoglycemic drug from Impaired Fasting Glycaemia similar mechanism of action, initial dose is determined depending on the deputy at the time of appointment of the drug, the replacement of another antidiabetic drug Central Nervous System remember deputy the effect of 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. Lymph Node The main effect of pharmaco-therapeutic effects of drugs: second generation sulfonylurea, which has relatively high selectivity of receptors?-Cells of the pancreas, a pancreatic and pancreatic effects beyond; stimulates production of insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients with diabetes 2 type stimulates the release of first phase insulin response to food intake and reduces the deputy from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on the absorption of glucose by cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, reduces the risk of mikrotromboziv reduction in blood glucose concentration was observed, on average, within 30 minutes after eating, after a maximum of 1,5 - 2 hours by insulinotropnoyi the drug, due to deputy release hlipizydu significantly reduced risk of Ointment effects. Sulfonylurea.